Richard Hopkins

ASX listed PharmAust has named Dr Richard Hopkins as the company’s new chief executive. Hopkins was previously running Perth biotech company Phylogica Limited and will start as PharmAust CEO on March 7. 

ASX listed PharmAust has taken a major step towards safeguarding the intellectual property of its promising anti-cancer drug after being granted a key patent in China. The patent strengthens the Perth-based company’s IP protection in a critical world market and provides protection for 16 years, with PharmAust expecting further patents to be issued in coming months.

Perth listed biotech PharmAust, have determined that their promising anti-cancer drug known as MPL might also be useful in the treatment of diabetes, brain disease and age related disorders. The company announced this week they have secured a patent for MPL in Australia relating to the treatment of the three newly targeted illnesses. 

PharmAust’s trials of its promising anti-cancer drug in dogs have produced encouraging early results, reducing the size of tumours in three out of four dogs with no other treatment. The early-stage trials have also shown it will be safe to give dogs significantly higher doses, which could lead to some spectacular results in the next stage of trials.

PharmAust has secured a patent for its promising anti-cancer drug in another major market, this week adding Japan to a list that already includes Australia, China and the US. The new protection is the latest in a series of recent patent awards that are clearly impressing the market, with PharmAust stock up almost 50% in the past month.

Successful clinical trials have led PharmAust to lock down patents for its promising anti-cancer drug in key markets around the world in rapid succession. Research work has indicated the drug might also be effective in combating non-cancer ailments such as brain disease and diabetes, leading to another non-cancer related patent being secured in Europe this week. 

PharmAust has engaged Canadian pharmaceutical specialist BRI to reformulate its promising anti-cancer drug Monepantel in readiness for more clinical trials and commercialisation. Monepantel has already shown positive outcomes treating cancer and PharmAust are now looking to improve the taste profile and palatability of the drug.

Perth based medical research pioneer Epichem, a wholly owned subsidiary of ASX listed PharmAust, has posted record revenues for FY17 on the back of growth across all of its business divisions. PharmAust said Epichem generated a best-ever revenue result of $3.05m for the 12 months to June, up by 30 per cent when compared to the previous year.  

Perth-listed biotech PharmAust has signed a deal with a leading Japanese chemical company that will give the ASX listed company rights to a library of 50 patents over promising anti-cancer agents. The new patents will complement the development of PharmAust’s main anti-cancer drug Monepantel, which has already shown positive results in fighting cancer.

ASX-listed biotech PharmAust has been granted a core patent in Europe relating to the use of “aminoacetonitrile derivatives” as potent kinase inhibitors for the treatment of cancer. The patent is another positive step for Perth-based company in shoring up its global IP protections. It follows the granting of similar patents in key markets including the US, Australia and China.

ASX listed biotech Company PharmAust has made significant progress in reformulating its promising anti-cancer drug Monepantel to improve its taste and deliver increased dosages of the substance in each pill. Monepantel has already shown pleasing results in initial clinical trials as a cancer treatment in humans and canines, with further tests of the drug planned for 2018.

ASX-listed biotech PharmAust has secured a patent in the US relating to the use of its promising anti-cancer drug Monepantel, for the treatment of non-cancerous conditions such as neurodegenerative diseases, diabetes and age-related illnesses. The patent is another move by Perth-based PharmAust to boost its global IP protections and follows the granting of patents in Europe, US, Australia and China.

ASX-listed biotech PharmAust has hit several key milestones in the development of its promising anti-cancer drug Monepantel, or MPL as it is commonly known. The company says reformulation of the potential breakthrough anti-cancer substance is progressing well, with its Canadian partner, BRI Pharmaceutical Research, achieving long awaited improvements on taste and dosage capacity.

ASX-listed biotech PharmAust continues to bolster its IP safeguards around its portfolio of anti-cancer treatments, securing a key patent in the US. The latest patent, which secures PharmAust’s IP in the major North American market, relates to the use of a library of cancer fighting compounds owned by Perth-based PharmAust after being developed by Japanese pharma Nihon Nohyaku.

PharmAust’s acquisition last month of a library of compounds from a major Japanese pharmaceutical company is looking like a shrewd move. Initial tests show some of the newly acquired compounds can kill cancer cells grown in-vitro up to six times more effectively than the parent compound, Monepantel, which is Pharmaust's flagship anti-cancer drug.